$0.44 EPS Expected for Boston Scientific Co. (NYSE:BSX) This Quarter

Share on StockTwits

Equities analysts expect Boston Scientific Co. (NYSE:BSX) to post $0.44 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Boston Scientific’s earnings, with the lowest EPS estimate coming in at $0.43 and the highest estimate coming in at $0.45. Boston Scientific reported earnings per share of $0.39 during the same quarter last year, which suggests a positive year-over-year growth rate of 12.8%. The company is scheduled to report its next quarterly earnings report on Wednesday, February 5th.

According to Zacks, analysts expect that Boston Scientific will report full year earnings of $1.56 per share for the current year, with EPS estimates ranging from $1.55 to $1.58. For the next year, analysts anticipate that the company will post earnings of $1.79 per share, with EPS estimates ranging from $1.73 to $1.86. Zacks’ EPS calculations are an average based on a survey of research firms that cover Boston Scientific.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.01. Boston Scientific had a net margin of 10.49% and a return on equity of 23.47%. The business had revenue of $2.71 billion during the quarter, compared to the consensus estimate of $2.68 billion. During the same quarter in the prior year, the firm earned $0.35 EPS. The company’s revenue for the quarter was up 13.1% compared to the same quarter last year.

BSX has been the subject of several recent analyst reports. Guggenheim set a $53.00 target price on shares of Boston Scientific and gave the stock a “buy” rating in a research report on Friday, October 25th. Piper Jaffray Companies set a $50.00 target price on shares of Boston Scientific and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Leerink Swann set a $50.00 target price on shares of Boston Scientific and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Raymond James decreased their target price on shares of Boston Scientific from $50.00 to $48.00 and set a “strong-buy” rating for the company in a research report on Monday, October 14th. Finally, ValuEngine cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. Three equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $47.07.

In other news, SVP Maulik Nanavaty sold 34,035 shares of the stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $42.65, for a total value of $1,451,592.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Arthur C. Butcher sold 6,329 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $41.98, for a total transaction of $265,691.42. The disclosure for this sale can be found here. Insiders sold 86,449 shares of company stock valued at $3,576,948 over the last quarter. Insiders own 0.66% of the company’s stock.

Several institutional investors have recently bought and sold shares of BSX. Alps Advisors Inc. lifted its stake in Boston Scientific by 12.2% during the second quarter. Alps Advisors Inc. now owns 17,230 shares of the medical equipment provider’s stock valued at $741,000 after purchasing an additional 1,874 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Boston Scientific by 2.2% during the second quarter. Charles Schwab Investment Management Inc. now owns 5,654,915 shares of the medical equipment provider’s stock valued at $243,049,000 after purchasing an additional 119,294 shares during the last quarter. North Star Investment Management Corp. acquired a new stake in Boston Scientific during the third quarter valued at approximately $89,000. Cullen Frost Bankers Inc. lifted its stake in Boston Scientific by 28.7% during the second quarter. Cullen Frost Bankers Inc. now owns 407,826 shares of the medical equipment provider’s stock valued at $17,528,000 after purchasing an additional 90,900 shares during the last quarter. Finally, MidWestOne Financial Group Inc. acquired a new stake in Boston Scientific during the second quarter valued at approximately $444,000. Institutional investors and hedge funds own 91.60% of the company’s stock.

Shares of NYSE:BSX traded down $0.19 during trading on Friday, reaching $41.51. 7,139,066 shares of the company’s stock traded hands, compared to its average volume of 9,872,340. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.31 and a quick ratio of 1.04. Boston Scientific has a 12 month low of $31.56 and a 12 month high of $43.84. The company has a 50 day moving average of $40.51 and a 200-day moving average of $40.46. The stock has a market capitalization of $58.09 billion, a P/E ratio of 28.24, a price-to-earnings-growth ratio of 2.34 and a beta of 0.76.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

See Also: How Buying a Call Option Works

Get a free copy of the Zacks research report on Boston Scientific (BSX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.